NCT05017415

Brief Summary

Until now, the use of invasive urodynamics with use of catheters is still the gold standard for lower urinary tract evaluation in subjects with CP. This suggests a psychological and physical impact of invasive urodynamics in subjects with CP and further demonstrates the need to avoid standard use of invasive urodynamics in children and adults with CP. The current study will evaluate usefulness of uroflowmetry, correlation between uroflowmetry parameters and different lower urinary tract symptoms will be investigated. Secondly, results of uroflowmetry indicating possible vulnerability of the upper urinary tract will be defined.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
56

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 16, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 23, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

October 14, 2021

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
Last Updated

September 19, 2024

Status Verified

September 1, 2024

Enrollment Period

1.7 years

First QC Date

August 16, 2021

Last Update Submit

September 5, 2024

Conditions

Keywords

cerebral palsylower urinary tract symptomsincontinenceuroflow measurement

Outcome Measures

Primary Outcomes (3)

  • Amount of pathological uroflow patterns - Qualitative assessment

    Interpretation by pediatric urologist following ICCS classification Measured during uroflowmetry

    During cross-sectional testing

  • Amount of pathological uroflow patterns - Quantitative assessment

    Interpretation using Flow index methodology Measured during uroflowmetry

    During cross-sectional testing

  • Maximal flow

    Measured during uroflowmetry Qmax (mililitres/seconds

    During cross-sectional testing

Secondary Outcomes (3)

  • Influencing factors for uroflow measurement

    During cross-sectional testing

  • Voided volume

    During cross-sectional testing

  • Post void residual urine

    During cross-sectional testing

Study Arms (2)

Standard toilet chair (hip angle 90°)

EXPERIMENTAL

uroflow measurement with subsequent post void residual measurement, conducted on a standard toilet chair.

Device: uroflow measurementDevice: Bladder ultrasound

Toilet chair with decreased hip angle

EXPERIMENTAL

uroflow measurement with subsequent post void residual measurement, conducted on a toilet chair with decreased hip angle.

Device: uroflow measurementDevice: Bladder ultrasound

Interventions

Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie

Also known as: uroflowmetry
Standard toilet chair (hip angle 90°)Toilet chair with decreased hip angle

Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700

Also known as: US
Standard toilet chair (hip angle 90°)Toilet chair with decreased hip angle

Eligibility Criteria

Age5 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Diagnosis of cerebral palsy
  • Dutch or French speaking child and parent

You may not qualify if:

  • History of urological surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ghent University Hospital

Ghent, Flanders, 9000, Belgium

Location

MeSH Terms

Conditions

Cerebral PalsyLower Urinary Tract Symptoms

Condition Hierarchy (Ancestors)

Brain Damage, ChronicBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Bieke Samijn, dr.

    Ghent University Hospital/Ghent University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
SCREENING
Intervention Model
PARALLEL
Model Details: Children will be randomised in two groups, with evaluation with a standard toilet seat or a toilet seat with decreased hip angle.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 16, 2021

First Posted

August 23, 2021

Study Start

October 14, 2021

Primary Completion

June 30, 2023

Study Completion

June 30, 2023

Last Updated

September 19, 2024

Record last verified: 2024-09

Locations